Decay-accelerating factor attenuates remote ischemia-reperfusion-initiated organ damage

Clinical Immunology

Volumn 124, Issue 3, 2007, Pages 311-327

  Weeks, Christine ^a,b   Moratz, Chantal ^c   Zacharia, Athina ^c   Stracener, Catherine ^b   Egan, Ryan ^c   Peckham, Russell ^b   Moore Jr , Francis D ^a   Tsokos, George C ^b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell surface molecules; Complement; Inflammation; Ischemia reperfusion; Lung

Indexed keywords

COBROTOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG MECHANISM; HINDLIMB; INTESTINE INJURY; ISCHEMIA; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; SEPSIS; SKELETAL MUSCLE; THERAPY EFFECT;

ANIMALS; ANTIGENS, CD55; DISEASE MODELS, ANIMAL; HINDLIMB; INTESTINES; LUNG; MESENTERY; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUSCLE, SKELETAL; REPERFUSION INJURY; SEPSIS; SOLUBILITY; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 34547837704     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.05.010     Document Type: Article

References (77)

1. Hill J.H., and Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J. Exp. Med. 133 (1971) 885-900
2. Weisman H.F., Bartow T., Leppo M.K., Marsh Jr. H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., and Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990) 146-151
3. Eror A.T., Stojadinovic A., Starnes B.W., Makrides S.C., Tsokos G.C., and Shea-Donohue T. Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin. Immunol. 90 (1999) 266-275
4. Huang J., Kim L.J., Mealey R., Marsh Jr. H.C., Zhang Y., Tenner A.J., Connolly Jr. E.S., and Pinsky D.J. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285 (1999) 595-599
5. Chai P.J., Nassar R., Oakeley A.E., Craig D.M., Quick Jr. G., Jaggers J., Sanders S.P., Ungerleider R.M., and Anderson P.A. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 101 (2000) 541-546
6. Hill J., Lindsay T.F., Ortiz F., Yeh C.G., Hechtman H.B., and Moore Jr. F.D. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149 (1992) 1723-1728
7. Zhao H., Montalto M.C., Pfeiffer K.J., Hao L., and Stahl G.L. Murine model of gastrointestinal ischemia associated with complement-dependent injury. J. Appl. Physiol. 93 (2002) 338-345
8. Weiser M.R., Williams J.P., Moore Jr. F.D., Kobzik L., Ma M., Hechtman H.B., and Carroll M.C. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183 (1996) 2343-2348
9. Williams J.P., Pechet T.T., Weiser M.R., Reid R., Kobzik L., Moore Jr. F.D., Carroll M.C., and Hechtman H.B. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 86 (1999) 938-942
10. Fleming S.D., Shea-Donohue T., Guthridge J.M., Kulik L., Waldschmidt T.J., Gipson M.G., Tsokos G.C., and Holers V.M. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 169 (2002) 2126-2133
11. Reid R.R., Woodcock S., Shimabukuro-Vornhagen A., Austen Jr. W.G., Kobzik L., Zhang M., Hechtman H.B., Moore Jr. F.D., and Carroll M.C. Functional activity of natural antibody is altered in Cr2-deficient mice. J. Immunol. 169 (2002) 5433-5440
12. Zhang M., Austen Jr. W.G., Chiu I., Alicot E.M., Hung R., Ma M., Verna N., Xu M., Hechtman H.B., Moore Jr. F.D., and Carroll M.C. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3886-3891
13. Austen Jr. W.G., Zhang M., Chan R., Friend D., Hechtman H.B., Carroll M.C., and Moore Jr. F.D. Murine hindlimb reperfusion injury can be initiated by a self-reactive monoclonal IgM. Surgery 136 (2004) 401-406
14. Zhang M., Alicot E.M., Chiu I., Li J., Verna N., Vorup-Jensen T., Kessler B., Shimaoka M., Chan R., Friend D., Mahmood U., Weissleder R., Moore F.D., and Carroll M.C. Identification of the target self-antigens in reperfusion injury. J. Exp. Med. 203 (2006) 141-152
15. Fleming S.D., Monestier M., and Tsokos G.C. Accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. J. Immunol. 173 (2004) 4230-4235
16. Fleming S.D., Egan R.P., Chai C., Girardi G., Holers V.M., Salmon J., Monestier M., and Tsokos G.C. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J. Immunol. 173 (2004) 7055-7061
17. Karpel-Massler G., Fleming S.D., Kirschfink M., and Tsokos G.C. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J. Surg. Res. 115 (2003) 247-256
18. Wada K., Montalto M.C., and Stahl G.L. Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 120 (2001) 126-133
19. Arumugam T.V., Shiels I.A., Strachan A.J., Abbenante G., Fairlie D.P., and Taylor S.M. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 63 (2003) 134-142
20. de Vries B., Kohl J., Leclercq W.K., Wolfs T.G., van Bijnen A.A., Heeringa P., and Buurman W.A. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J. Immunol. 170 (2003) 3883-3889
21. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., Tsokos G.C., and Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 115 (2005) 2444-2453
22. Lukacik P., Roversi P., White J., Esser D., Smith G.P., Billington J., Williams P.A., Rudd P.M., Wormald M.R., Harvey D.J., Crispin M.D., Radcliffe C.M., Dwek R.A., Evans D.J., Morgan B.P., Smith R.A., and Lea S.M. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1279-1284
23. Lea S. Interactions of CD55 with non-complement ligands. Biochem. Soc. Trans. 30 (2002) 1014-1019
24. Medof M.E., Lublin D.M., Holers V.M., Ayers D.J., Getty R.R., Leykam J.F., Atkinson J.P., and Tykocinski M.L. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 2007-2011
25. Herbert A., O'leary J., Krych-Goldberg M., Atkinson J.P., and Barlow P.N. Three-dimensional structure and flexibility of proteins of the RCA family - a progress report. Biochem. Soc. Trans. 30 (2002) 990-996
26. Miwa T., and Song W.C. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int. Immunopharmacol. 1 (2001) 445-459
27. Williams P., Chaudhry Y., Goodfellow I.G., Billington J., Powell R., Spiller O.B., Evans D.J., and Lea S. Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J. Biol.Chem. 278 (2003) 10691-10696
28. Kim D.D., and Song W.C. Membrane complement regulatory proteins. Clin. Immunol. 118 (2006) 127-136
29. Song W.C. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr. Dir. Autoimmun. 7 (2004) 181-199
30. Song W.C., Sarrias M.R., and Lambris J.D. Complement and innate immunity. Immunopharmacology 49 (2000) 187-198
31. Brodbeck W.G., Mold C., Atkinson J.P., and Medof M.E. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J. Immunol. 165 (2000) 3999-4006
32. Kroshus T.J., Salerno C.T., Yeh C.G., Higgins P.J., Bolman III R.M., and Dalmasso A.P. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation 69 (2000) 2282-2289
33. Medof M.E., Kinoshita T., and Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 160 (1984) 1558-1578
34. Holers V.M., Kinoshita T., and Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol. Today 13 (1992) 231-236
35. Sogabe H., Nangaku M., Ishibashi Y., Wada T., Fujita T., Sun X., Miwa T., Madaio M.P., and Song W.C. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J. Immunol. 167 (2001) 2791-2797
36. Liu J., Miwa T., Hilliard B., Chen Y., Lambris J.D., Wells A.D., and Song W.C. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201 (2005) 567-577
37. Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N., Xu Y., and Medof M.E. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201 (2005) 1523-1530
38. Shimizu I., Smith N.R., Zhao G., Medof E., and Sykes M. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 81 (2006) 95-100
39. Ghebremariam Y.T., Smith S.A., Anderson J.B., Kahn D., and Kotwal G.J. Intervention strategies and agents mediating the prevention of xenorejection. Ann. N. Y. Acad. Sci. 1056 (2005) 123-143
40. Lublin D.M. Review: Cromer and DAF: role in health and disease. Immunohematology 21 (2005) 39-47
41. Verbakel C.A., van Duikeren S., de Bruin R.W., Marquet R.L., and IJzermans J.N. Human decay-accelerating factor expressed on rat hearts inhibits leukocyte adhesion. Transpl. Int. 16 (2003) 168-172
42. Yamada K., Miwa T., Liu J., Nangaku M., and Song W.C. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J. Immunol. 172 (2004) 3869-3875
43. Schafer H., Mathey D., Hugo F., and Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J. Immunol. 137 (1986) 1945-1949
44. Robert-Offerman S.R., Leers M.P., van Suylen R.J., Nap M., Daemen M.J., and Theunissen P.H. Evaluation of the membrane attack complex of complement for the detection of a recent myocardial infarction in man. J. Pathol. 191 (2000) 48-53
45. Homeister J.W., Satoh P., and Lucchesi B.R. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ. Res. 71 (1992) 303-319
46. Austen Jr. W.G., Kyriakides C., Favuzza J., Wang Y., Kobzik L., Moore Jr. F.D., and Hechtman H.B. Intestinal ischemia-reperfusion injury is mediated by the membrane attack complex. Surgery 126 (1999) 343-348
47. Fleming S.D., Mastellos D., Karpel-Massler G., Shea-Donohue T., Lambris J.D., and Tsokos G.C. C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. Clin. Immunol. 108 (2003) 263-273
48. Kilgore K.S., Park J.L., Tanhehco E.J., Booth E.A., Marks R.M., and Lucchesi B.R. Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion. J. Mol. Cell. Cardiol. 30 (1998) 75-85
49. Ito W., Schafer H.J., Bhakdi S., Klask R., Hansen S., Schaarschmidt S., Schofer J., Hugo F., Hamdoch T., and Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc. Res. 32 (1996) 294-305
50. Zhou W., Farrar C.A., Abe K., Pratt J.R., Marsh J.E., Wang Y., Stahl G.L., and Sacks S.H. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 105 (2000) 1363-1371
51. Lupia E., Del Sorbo L., Bergerone S., Emanuelli G., Camussi G., and Montrucchio G. The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils. Immunology 109 (2003) 557-563
52. Cooke K.R., Kobzik L., Martin T.R., Brewer J., Delmonte Jr. J., Crawford J.M., and Ferrara J.L. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88 (1996) 3230-3239
53. Chan R.K., Ding G., Verna N., Ibrahim S., Oakes S., Austen Jr. W.G., Hechtman H.B., and Moore Jr. F.D. IgM binding to injured tissue precedes complement activation during skeletal muscle ischemia-reperfusion. J. Surg. Res. 122 (2004) 29-35
54. Yassin M.M., Harkin D.W., Barros D'Sa A.A., Halliday M.I., and Rowlands B.J. Lower limb ischemia-reperfusion injury triggers a systemic inflammatory response and multiple organ dysfunction. World J. Surg. 26 (2002) 115-121
55. Mukundan C., Gurish M.F., Austen K.F., Hechtman H.B., and Friend D.S. Mast cell mediation of muscle and pulmonary injury following hindlimb ischemia-reperfusion. J. Histochem. Cytochem. 49 (2001) 1055-1056
56. Kyriakides C., Favuzza J., Wang Y., Austen Jr. W.G., Moore Jr. F.D., and Hechtman H.B. Recombinant soluble P-selectin glycoprotein ligand 1 moderates local and remote injuries following experimental lower-torso ischaemia. Br. J. Surg. 88 (2001) 825-830
57. Maier S., Traeger T., Entleutner M., Westerholt A., Kleist B., Huser N., Holzmann B., Stier A., Pfeffer K., and Heidecke C.D. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 21 (2004) 505-511
58. Tao W., Deyo D.J., Traber D.L., Johnston W.E., and Sherwood E.R. Hemodynamic and cardiac contractile function during sepsis caused by cecal ligation and puncture in mice. Shock 21 (2004) 31-37
59. Kirschfink M. Targeting complement in therapy. Immunol. Rev. 180 (2001) 177-189
60. Nielsen E.W., Mollnes T.E., Harlan J.M., and Winn R.K. C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping. Scand. J. Immunol. 56 (2002) 588-592
61. Inderbitzin D., Beldi G., Avital I., Vinci G., and Candinas D. Local and remote ischemia-reperfusion injury is mitigated in mice overexpressing human C1 inhibitor. Eur. Surg. Res. 36 (2004) 142-147
62. Buerke M., Schwertz H., Seitz W., Meyer J., and Darius H. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J. Immunol. 167 (2001) 5375-5380
63. Buerke M., Murohara T., and Lefer A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91 (1995) 393-402
64. Horstick G., Heimann A., Gotze O., Hafner G., Berg O., Boehmer P., Becker P., Darius H., Rupprecht H.J., Loos M., Bhakdi S., Meyer J., and Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 95 (1997) 701-708
65. Arumugam T.V., Woodruff T.M., Stocks S.Z., Proctor L.M., Pollitt S., Shiels I.A., Reid R.C., Fairlie D.P., and Taylor S.M. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J. Hepatol. 40 (2004) 934-941
66. Campbell W., Okada N., and Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180 (2001) 162-167 (Ref Type: Generic)
67. Lublin D.M., and Atkinson J.P. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7 (1989) 35-58
68. Nicholson-Weller A., March J.P., Rosenfeld S.I., and Austen K.F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 5066-5070
69. Pangburn M.K., Schreiber R.D., and Muller-Eberhard H.J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 5430-5434
70. Rosse W.F., and Parker C.J. Paroxysmal nocturnal haemoglobinuria. Clin. Haematol. 14 (1985) 105-125
71. Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., and Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129 (1982) 184-189
72. Parker C.J. Historical aspects of paroxysmal nocturnal haemoglobinuria: 'defining the disease'. Br. J. Haematol. 117 (2002) 3-22
73. Miwa T., Maldonado M.A., Zhou L., Sun X., Luo H.Y., Cai D., Werth V.P., Madaio M.P., Eisenberg R.A., and Song W.C. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am. J. Pathol. 161 (2002) 1077-1086
74. Christiansen D., Milland J., Thorley B.R., McKenzie I.F.C., and Loveland B.E. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur. J. Immunol. 26 (1996) 578-585
75. Harris C.L., Spiller O.B., and Morgan B.P. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement inhibiting activities. Immunology 100 (2000) 462-470
76. Pangburn M.K. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. J. Immunol. 136 (1986) 2216-2221
77. Harris C.L., Abbott R.J., Smith R.A., Morgan B.P., and Lea S.M. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J. Biol. Chem. 280 (2005) 2569-2578